February 21, 2020Open Access

MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

Treatment with next-generation ALK inhibitors, particularly in the first-line setting, may lead to MET-driven resistance. Patients with acquired MET alterations may derive clinical benefit from therapies that target both ALK and MET.

MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer

Key Points

Abstract

Cite This Study

Also Consider

Also Consider